FoundationOne in
colon cancer

FoundationOne can potentially match clinically relevant alterations found in colon cancer samples to novel, targeted cancer treatment options and clinical trials.1,28 This may then assist the physician in tailoring patient management. To date, FoundationOne has generated over xxx colon cancer cancer profiles. These profiles continue to facilitate the advancement of FoundationCORE, the Foundation Medicine comprehensive genomic database.6 FoundationOne can be used to profile all types of solid tumours, including colon cancer tumours such as colorectal adenocarcinoma.1,28

__

Using FoundationOne to identify alterations in colon cancer

FoundationOne interrogates the entire coding region of 315 cancer-related genes plus select introns from 28 genes.1 Unlike other more traditional diagnostic tools, Foundation Medicine also simultaneously identifies MSI status and TMB,2,3 with no additional tests, cost or turnaround time.

__

Clinical relevance of genomic profiling in colon cancer

There has been an increase in the number of known genomic alterations present in cancer in recent years. This increase in known targetable genetic drivers could potentially result in an increase in targeted therapies for patients with colon cancer,8,10,11  

 

In addition to genomic alterations, other biomarkers, such as MSI, could guide treatment decisions in patients with colon cancer. MSI can arise as a result of defects in DNA mismatch repair and occurs in approximately 15% of colorectal cancers.29,30 Previous studies have shown that MSI status can act as a predictive marker for clinical benefit with immunotherapy. Hence, broad molecular profiling using FoundationOne could potentially help to better tailor treatment options for MSI-high patients with colon cancer.28

Mutation frequencies in colorectal cancer
Mutation frequencies in colorectal cancer
swipe

Adapted from The Cancer Genome Atlas Netowrk, 2012.31

 

In order to identify the most appropriate targeted treatment for a colon cancer, there is a need for an accurate diagnostic test that identifies all clinically relevant alterations, in addition to MSI.5,8  

Is FoundationOne suitable for all cancer types?

FoundationOne is suitable for all types of solid tumour cancers, including rare cancers and cancers of unknown origin, and in recurrent or metastatic solid tumour cancers. FoundationOne can be used to profile all types of colon cancer tumours, including colorectal adenocarcinoma, recurrent and metastatic tumour types and those with high performance status.1,27

FoundationOne can be especially useful in cases where there are many possible treatment options to choose between, limited treatment options or where the solid tumour has uncommon or rare alterations that are not routinely tested for.1,7

Visit our Order page to find out how you can get started with FoundationOne
References
  1. FoundationOne technical information
  2. Rozenblum AB et al. J Thorac Oncol 2017; 2:258–268 (and supplementary material).
  3. Chalmers ZR et al. Genome Med 2017; 9:34.
  4. Genomeweb. Foundation Medicine Q3 revenues up 45 percent. Available at: https://www.genomeweb.com/molecular-diagnostics/foundation-medicine-q3-revenues-45-percent [accessed November 2017].
  5. Frampton, GM et al. Nat Biotechnol 2013; 31:1023–1031
  6. Foundation Medicine. FoundationCORE press release, June 2016.
  7. Schwaederle M et al. Mol Cancer Ther 2015; 14:1488–1494.
  8. Drilon A et al. Clin Cancer Res 2015; 21:3631–3639.
  9. Ross JS et al. Cancer 2016; 17:2654–2562.
  10. Hirsch FR et al. Lancet 2016; 388:1012–1024.
  11. Aitken M et al. Global Oncology Trend Report 2015. Available at: http://keionline.org/sites/default/files/IIHI_Oncology_Trend_Report_2015.pdf (accessed November 2017).
  12. Kos Z and Dabbs DJ. Histopathology 2016; 68:70–85.
  13. Bishop R. Bioscience Horizons 2010; 1:85–95.
  14. Chen AY-Y and Chen A. J Invest Dermatol 2013; 133:e8.
  15. Angulo B et al. PLoS One 2012; 8:e43842.
  16. Pao W and Girard N. Lancet Oncol 2011; 12:175–180.
  17. Jordan EJ et al. Cancer Discov 2017; 6:596–609.
  18. Ali SM et al. Oncologist 2016; 6:762–670.
  19. Suh JH et al. Oncologist 2016; 21:684–691.
  20. National Comprehensive Cancer Network (NCCN) NSCLC guidelines, Version 9, 2017.
  21. Dillon JL et al. The Breast 2016; 29:202–207.
  22. Stephens PJ et al. Nature 2012; 7403:400–404.
  23. Eralp Y. Tranl Oncogenomics 2016; 8:1–7.
  24. Schrock AB et al. Clin Cancer Res 2016; 22:3281–3285.
  25. Chmielecki J et al. Oncologist 2015; 20:7–12.
  26. Yuan Y et al. Oncotarget 2012: doi: 10.18632/oncotarget.14476.
  27. Roche Foundation Medicine data on file.
  28. Masucci GV et al. Int J Immunother Cancer Res 2016; 4:16.
  29. National Cancer Institute (NIH). NCI dictionary of cancer terms. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=285933 [accessed November 2017].
  30. Sinicrope FA. Nat Rev Clin Oncol 2010; 7:174–177.
  31. The Cancer Genome Atlas Network, Nature 2012; 487:330–337.